Combination therapy before surgery for early-onset stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 45 years old.
- You have been diagnosed with stomach or gastroesophageal junction cancer that can be removed with surgery.
- Your cancer has not spread to distant organs (stage M0) and is considered resectable after a team review.
- You are in good overall health (able to care for yourself, ECOG 0-1) and your organ function is adequate.
- You have not had prior chemotherapy, radiation, or immunotherapy for this cancer.
- You do not have HER2-positive or MSI-high tumors (certain genetic markers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.